BioCryst Pharmaceuticals Stock Forecast

Stock Price Forecast

The 11 analysts with 12-month price forecasts for BioCryst Pharmaceuticals stock have an average target of 20.82, with a low estimate of 9.00 and a high estimate of 32. The average target predicts an increase of 145.81% from the current stock price of 8.47.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$9.00	$20.82	$18	$32
Change	+6.26%	+145.81%	+112.51%	+277.80%

* Price targets were last updated on Jan 30, 2026.

Analyst Ratings

The average analyst rating for BioCryst Pharmaceuticals stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	4	4	5	5	5	5
Buy	6	6	6	5	5	5
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	12	11	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $14 → $13	Buy	Maintains	$14 → $13	+53.48%	Jan 30, 2026
Andrew S. Fein HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $30 → $32	Strong Buy	Maintains	$30 → $32	+277.80%	Dec 15, 2025
Jonathan Wolleben Citizens	Citizens	Buy Maintains $27 → $25	Buy	Maintains	$27 → $25	+195.16%	Nov 5, 2025
Gena Wang Barclays	Barclays	Hold Maintains $11 → $9	Hold	Maintains	$11 → $9	+6.26%	Nov 4, 2025
Serge Belanger Needham	Needham	Strong Buy Maintains $20 → $18	Strong Buy	Maintains	$20 → $18	+112.51%	Nov 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

663.77M

from 874.84M

-24.13%

from 874.84M

Revenue Next Year

747.06M

from 663.77M

12.55%

from 663.77M

EPS This Year

0.39

from 1.21

-67.50%

from 1.21

EPS Next Year

0.59

from 0.39

49.27%

from 0.39

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	157.17M	270.83M	331.41M	450.71M	874.84M	663.77M	747.06M
Revenue Growth	782.38%	72.32%	22.37%	36.00%	94.10%	-24.13%	12.55%
EPS	-1.03	-1.33	-1.18	-0.43	1.21	0.39	0.59
EPS Growth	-	-	-	-	-	-67.50%	49.27%
Forward PE	-	-	-	-	-	21.54	14.43
No. Analysts	-	-	-	-	-	12	12

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	695.1M	841.8M
Avg	663.8M	747.1M
Low	627.2M	672.8M

Revenue Growth

Revenue Growth	2026	2027
High	-20.5%	26.8%
Avg	-24.1%	12.5%
Low	-28.3%	1.4%

EPS Forecast

EPS	2026	2027
High	0.83	1.11
Avg	0.39	0.59
Low	0.01	0.01

EPS Growth

EPS Growth	2026	2027
High	-31.2%	183.1%
Avg	-67.5%	49.3%
Low	-99.2%	-97.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.